PT  - JOURNAL ARTICLE
AU  - Constantin Lapa
AU  - Heribert Hänscheid
AU  - Malte Kircher
AU  - Andreas Schirbel
AU  - Gerd Wunderlich
AU  - Rudolf A. Werner
AU  - Samuel Samnick
AU  - Jörg Kotzerke
AU  - Hermann Einsele
AU  - Andreas K. Buck
AU  - Hans-Jürgen Wester
AU  - Götz Ulrich Grigoleit
TI  - Feasibility of CXCR4-Directed Radioligand Therapy in Advanced Diffuse Large B-Cell Lymphoma
AID  - 10.2967/jnumed.118.210997
DP  - 2019 Jan 01
TA  - Journal of Nuclear Medicine
PG  - 60--64
VI  - 60
IP  - 1
4099  - http://jnm.snmjournals.org/content/60/1/60.short
4100  - http://jnm.snmjournals.org/content/60/1/60.full
SO  - J Nucl Med2019 Jan 01; 60
AB  - We have recently reported on our experience with C-X-C-motif chemokine receptor 4 (CXCR4)–directed radioligand therapy (RLT) in multiple myeloma and acute leukemia. Methods: Six patients with heavily pretreated relapsed diffuse large B-cell lymphoma (3 men, 3 women; aged, 54 ± 8 y) underwent CXCR4-directed RLT in combination with conditioning chemotherapy and allogeneic stem cell transplantation. In 2 patients, radioimmunotherapy targeting CD20 or CD66 was added to enhance antilymphoma activity. Endpoints were incidence and severity of adverse events, progression-free survival, and overall survival. Results: RLT and additional radioimmunotherapy were well tolerated, without any acute adverse events or changes in vital signs. Successful engraftment was recorded after a median of 11 d (range, 9–13 d). Of the 4 patients who were available for follow-up (one patient died of CNS aspergillosis 29 d after RLT and another of sepsis in aplasia 34 d after RLT), CXCR4-directed RLT resulted in a partial response in two (both treated with additional radioimmunotherapy) and a mixed response in the remaining two. The response duration was rather short-lived, with a median progression-free survival of 62 d (range, 29–110 d) and a median overall survival of 76 d (range, 29–334 d). Conclusion: CXCR4-directed RLT (in combination with additional radioimmunotherapy) is feasible as a conditioning regimen before allogeneic stem cell transplantation in diffuse large B-cell lymphoma.